Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved once-daily Wegovy (R) pill, the first oral GLP-1 medicine for obesity in the US. (3) Wegovy (R) pill is used ...

The FDA approved revumenib for relapsed/refractory (R/R) acute myeloid leukemia, offering a new targeted therapy option for patients with NPM1 mutations. According to the updated results presented at ...

Mantle cell lymphoma is the fourth subtype of non-Hodgkin lymphoma that can be treated with this CAR T-cell therapy. Bristol Myers Squibb today announced 1 that FDA has approved lisocabtagene ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

AUTX-703, a first-in-class oral KAT2A/B degrader, received FDA fast track designation for relapsed or refractory AML treatment. Promising preclinical data showed AUTX-703's effective KAT2A/B ...

Revuforj is approved for relapsed/refractory AML with NPM1 mutation in patients aged one year and older, based on AUGMENT-101 trial results. The drug inhibits menin's interaction with KMT2A, slowing ...

The FDA’s reported plan to move toward single-trial approvals has stirred industry concern, but one group of analysts views the proposal as a catalyst for greater R&D investment in the sector. Earlier ...

In the U.S., we pay approximately 2.5 times more than people in other countries. This matters, and it hurts; as much as one in four Americans cannot afford their medication. Unfortunately, the problem ...